Glympse Bio, Inc.
AcquiredCambridge, United States · Founded 2017 · $68.7M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- glympsebio.com
- Total Funding
- $68.7M
- Last Round
- $46.7M Series BJun 2020
- Rounds
- 2
- Acquisition Date
- Aug 2023
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 2 investors for this company. The full record is or through the API.
About
Glympse Bio developed engineered activity-based nanosensors (ABNs) to detect disease-associated protease activity in urine and blood, enabling non-invasive diagnostics for conditions including cancer and inflammatory diseases. The company merged with Sunbird Bio in 2023 to advance protein-based diagnostics for Alzheimer's and other neurological disorders.
Summary
Glympse Bio, Inc. is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $68.7M in total across 2 rounds, most recently a $46.7M Series B round in Jun 2020. Investors include Section 32 and CRV (Charles River).
Funding & Exit History
Aug 2023
Sign up to see all 3 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/glympse-bio-inc"><img src="https://indexed.vc/api/badge/company/glympse-bio-inc" alt="Glympse Bio, Inc. on Indexed.vc" width="260" height="76" /></a>